window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 14, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Scottish Medicines Consortium

  • Central Nervous System,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland

    Zilucoplan has been accepted for restricted use in NHS Scotland [...]

    August 11, 2026
  • Clinical & Regulatory

    Acarizax accepted for house dust mite allergy treatment in NHS Scotland

    Acarizax has been accepted for use in NHS Scotland for [...]

    August 11, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    SMC approves TALVEY for relapsed multiple myeloma in Scotland

    The Scottish Medicines Consortium (SMC) has accepted TALVEY (talquetamab) for [...]

    June 9, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    SMC accepts guselkumab for Crohn’s disease and ulcerative colitis in NHS Scotland

    The Scottish Medicines Consortium (SMC) has accepted guselkumab for the [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Circio and Full Circles Therapeutics combine technologies for in vivo cell therapy
    Categories: Advanced Therapies, Drug Delivery & Formulation, Drug Discovery & Development, Research & Development
  • Piramal Pharma reports 22.6% emissions reduction and zero OAI observations in sustainability report
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Research & Development
  • FDA approves ViiV’s Tivicay PD for young children with HIV
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top